MKI67 and diffuse large B-cell lymphoma: indicated that patients with DLBCL with the nongerminal center B‐cell‐like subtype (GCB) and high Ki‐67 expression had 3‐year OS and progression‐free survival rates of only 65.2% and 56.4%, respectively, which were significantly lower than those of patients with low Ki‐67 expression.11